

Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique

Mathieu Bastard,¹ Lucas Molfino,² Cláudia Mutaquiha,³ Miriam Arago Galindo,² Pereira Zindoga,³ Deise Vaz,² Ivan Mahinça,³ Philipp DuCros,⁴ Barbara Rusch,⁵ and Alex Telnov⁵

¹Epicentre, Paris, France; ²Médecins Sans Frontières, and ³Ministry of Health, Maputo, Mozambique; ⁴Burnet Institute, Melbourne, Australia; and ⁵Médecins Sans Frontières, Geneva, Switzerland

Bedaquiline was recommended by the World Health Organization as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regimens. However, no recommendation was given for the short MDR-TB regimen. Data from our small cohort of patients who switched from injectable drug to bedaquiline suggest that a bedaquiline-based short regimen is effective and safe.

Keywords. multidrug-resistant tuberculosis; short regimen; bedaquiline; treatment outcomes; injectable drugs.

Short standardized treatment for multidrug-resistant tuberculosis (MDR-TB) has been recommended by the World Health Organization (WHO) since 2016 for patients not previously treated with second-line agents and without second-line resistance [1, 2]. However, a significant proportion of patients experience numerous severe adverse events linked to the use of second-line injectable drugs including ototoxicity, nephrotoxicity, and electrolyte imbalance, which could lead to discontinuation of treatment or to permanent physical injury to patients [3].

In 2018, WHO revised its recommendations about MDR-TB treatment regimens [4]. The use of kanamycin and capreomycin are no longer recommended in the long regimen and bedaquiline is preferred. However, due to lack of evidence, bedaquiline is not recommended for the short regimen and the only modification is a recommendation to replace kanamycin with amikacin. WHO encourages field evaluation of modified shorter MDR-TB regimens including bedaquiline instead of injectable drugs.

In 2015, Médecins Sans Frontières (MSF) launched a prospective study to describe the efficacy of the short MDR-TB regimen in Maputo, Mozambique. Patients who experienced adverse events that could be attributed to one specific drug could remain on the short MDR-TB regimen with the causative agent replaced by bedaquiline.

In this article, we report the outcomes of patients started on a short standardized MDR-TB regimen in whom the injectable drug was replaced with bedaquiline due to adverse events.

METHODS

Beginning in 2015, we have conducted a prospective longitudinal study in Maputo, Mozambique, where MSF provides support to the Ministry of Health for drug-resistant tuberculosis. The study population consisted of all patients with active pulmonary tuberculosis diagnosed as rifampicin resistant by Xpert or phenotypic drug susceptibility testing (DST). Patients resistant to fluoroquinolones alone or to fluoroquinolones and injectables were excluded from the study. Patients resistant to injectable agents (kanamycin and capreomycin) continued the short regimen if, once the DST results were available, their clinical condition improved compared to baseline. If the clinical condition worsened or remained the same, they were withdrawn from the study and switched to a more appropriate regimen. Additional resistance to a drug in the regimen was not a criteria for exclusion.

The regimen consisted of an intensive phase with pyrazinamide, ethambutol, isoniazid, moxifloxacin, kanamycin, prothionamide, and clofazimine for at least 4 months and a continuation phase with pyrazinamide, ethambutol, moxifloxacin, prothionamide, and clofazimine for a fixed 5-month duration. Patients could continue with a short regimen with bedaquiline in the following cases: grade 2 and higher ototoxicity associated with kanamycin, grade 3 and higher nephrotoxicity associated with kanamycin, and grade 3 and higher gastrointestinal disorders associated with prothionamide. In such cases, the causative drug was stopped and replaced by bedaquiline at standard dosage for 6 months. Culture and DST were performed at the Institute of Tropical Medicine (ITM) in Antwerp, Belgium. Patients were eligible for this analysis if they started short MDR-TB treatment and if kanamycin was replaced by bedaquiline due to adverse events. Database censoring was performed on 31 August 2018.

We described the characteristics of eligible patients and the reasons and timing of switching from kanamycin to bedaquiline. MDR-TB treatment outcomes were defined per WHO definitions: cured (treatment completed without evidence of failure and 3 or more consecutive cultures taken

Received 18 January 2019; editorial decision 26 February 2019; accepted 4 March 2019; published online March 11, 2019.

Correspondence: M. Bastard, Epicentre, 8 rue Saint Sabin, 75011 Paris, France (mathieu.bastard@geneva.msf.org).

Clinical Infectious Diseases® 2019;XX(X):1–3

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/cid/ciz196

at least 30 days apart are negative after the intensive phase); treatment completed (treatment completed without evidence of failure but no record that ≥ 3 consecutive cultures taken at least 30 days apart are negative after the intensive phase); death; treatment failure; and lost to follow-up [5]. Culture conversion was defined as 2 consecutive negative cultures >28 days apart. Adverse events were assessed according to the Division of AIDS grading score. Analyses were performed with Stata version 15 software (StataCorp, College Station, Texas).

This study was approved by the ethical review boards of MSF, ITM Belgium, and Mozambique (Comite nacional de bioetica para a saude - CNBS). All treatment was provided free of charge irrespective of participation in the study. Participation was voluntary after written informed consent.

RESULTS

A total of 164 patients starting a short MDR-TB treatment regimen were included between November 2015 and May 2018. Among them, 19 (11.6%) switched from kanamycin to bedaquiline due to adverse events. The main reason to stop kanamycin was ototoxicity (17/19 [89.5%]); 1 patient experienced nephrotoxicity and another hypokalemia.

Characteristics of these patients are presented in Table 1: 57.9% were male, the median age was 35 years (IQR 26–48 years), median BMI was 17.6 kg/m² (IQR, 15.8–19.9 kg/m²), and 63.2% were HIV infected. Among them, 14 (73.7%) were new TB cases, 4 (21.0%) were previously treated with first-line drugs and relapsed, and 1 (5.3%) was previously treated with first-line drug and failed previous treatment. At treatment initiation, 14 of 19 (73.7%) were culture positive and DST showed that 6 (31.6%) were resistant to streptomycin, 7 (36.8%) were resistant to ethambutol, 7 (36.8%) were resistant to pyrazinamide, and 7 (36.8%) were resistant to ethionamide. No patients were resistant to fluoroquinolones or injectable drugs. In total, 7 (36.8%) of the patients were resistant to >1 drug among the previous drugs listed, and 6 (31.6%) were resistant to >2 drugs.

The median time from treatment start to switching kanamycin to bedaquiline was 2.76 months (IQR, 2.20–3.61 months) and the median duration of treatment with bedaquiline was 24 weeks (IQR, 24–26 weeks) after switch.

Among the 16 patients who started the short MDR-TB regimen before 1 October 2017 (11 months prior to censoring date), 13 of 16 (81.3%) were cured, and 3 of 16 (18.7%) completed treatment (Table 1). Taken together, we observed 100% treatment success among patients who switched kanamycin to bedaquiline. Among the other 3 patients still on treatment, 3 (100%) had already converted culture in the first 4 months of treatment.

All 5 patients who were culture negative at treatment start remained culture negative during the whole treatment length.

Table 1. Characteristics and Outcomes of the 19 Patients Who Switched From Kanamycin to Bedaquiline During a Short Multidrug-resistant Tuberculosis Regimen in Mozambique

Characteristics	No. (%)
Sex	
Male	11 (57.9)
Female	8 (42.1)
Age, y, median (IQR)	35 (26–48)
BMI, kg/m ² , median (IQR)	17.6 (15.8–19.9)
HIV status	
Negative	7 (36.8)
Positive	12 (63.2)
On ART at MDR-TB treatment start	7 (58.3)
Receive ART at MDR-TB treatment start	5 (41.7)
Antiretroviral therapy	
TDF/3TC/EFV	5 (41.7)
AZT/3TC/EFV	3 (25.0)
ABC/3TC/EFV	2 (16.7)
ABC/3TC/NVP	1 (8.3)
AZT/3TC/LPV/r	1 (8.3)
TB treatment history	
New case	14 (73.7)
Previously treated with first-line drugs (relapse)	4 (21.0)
Previously treated with first-line drugs (treatment failure)	1 (5.3)
Culture results	
Negative for MTB	5 (26.3)
Positive for MTB	14 (73.7)
DST results	
Streptomycin resistance	6 (31.6)
Ethambutol resistance	7 (36.8)
Pyrazinamide resistance	7 (36.8)
Ethionamide resistance	7 (36.8)
Injectable resistance	0 (0.0)
Fluoroquinolone resistance	0 (0.0)
Resistance to >1 drug	7 (36.8)
Resistance to >2 drugs	6 (31.6)
Treatment outcomes	n = 16
Cured	13 (81.3)
Treatment completed	3 (18.7)
Death	0
Failure	0
Lost to follow-up	0
Still on treatment	n = 3
Culture conversion	3 (100)

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; AZT, azidothymidine; BMI, body mass index; DST, drug susceptibility test; EFV, efavirenz; HIV, human immunodeficiency virus; IQR, interquartile range; LPV/r, lopinavir/ritonavir; MDR, multidrug-resistant; MTB, *Mycobacterium tuberculosis*; NVP, nevirapine; TB, tuberculosis; TDF, tenofovir disoproxil fumarate.

Among the 14 patients who were culture positive at treatment start, 9 were already culture negative at bedaquiline start and 5 were still positive when bedaquiline was started.

No aspartate aminotransferase/alanine aminotransferase increases and no grade 3 or 4 QT prolongation were observed on monthly electrocardiograms (ECGs) during the time that patients received bedaquiline.

DISCUSSION

Among our small cohort of 19 patients, we observed a high proportion of favorable outcomes and no major safety issues among those switched from an injectable drug to bedaquiline on a short MDR-TB regimen in Mozambique.

At bedaquiline initiation, most patients were already culture negative, which limits the interpretation about the efficacy of bedaquiline. Twelve-month relapse-free rate was not possible to assess at the time of analysis. However, toxicity of injectable agents is extremely common during MDR-TB treatment and is a major concern for the success of MDR-TB treatment [3]. The proportion of patients who experienced hearing loss or other ototoxicity (potentially eligible for switching from injectable drug to bedaquiline) might be even higher than in this study since some patients might die before developing ototoxicity. At the same time, no evidence of major safety issues with bedaquiline were demonstrated; QT interval prolongation is known to be associated with bedaquiline, but very few episodes are of clinical relevance [6, 7]. These episodes could be handled safely with temporary interruption of cardiotoxic drugs together with a regular monitoring of ECG [8]. Recent studies have already shown the efficacy of bedaquiline among patients resistant to second-line drugs using a long MDR-TB treatment regimen [9–12].

Many programs are considering implementation of an all-oral short regimen. Although more data on a short regimen with bedaquiline are needed, data from our small cohort suggest that a bedaquiline-based short standardized regimen is effective and safe, and that patients who developed ototoxicity, including hearing loss, during short MDR-TB regimens may continue with the short regimen by replacing the injectable agent with bedaquiline, instead of switching to longer MDR-TB treatment.

Notes

Author contributions. Conception and design: M. B., L. M., P. d. C., A. T. Analysis: M. B., A. T. Interpretation of results: M. B., L. M., C. M., M. A. G., P. Z., D. V., I. M., P. d. C., B. R., A. T. Drafting the manuscript for important intellectual content: all authors.

Financial support. Médecins Sans Frontières provided the funding for this study.

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Available at: <http://apps.who.int/iris/bitstream/handle/10665/250125/9789241549639-eng.pdf;jsessionid=1D555B3ADA03BD140BC12D6A074643DE?sequence=1>. Accessed 10 January 2019.
2. Trébucq A, Schwoebel V, Kashongwe Z, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. *Int J Tuberc Lung Dis* 2018; 22:17–25.
3. Reuter A, Tisile P, von Delft D, et al. The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? *Int J Tuberc Lung Dis* 2017; 21:1114–26.
4. World Health Organization. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). 2018. Available at: http://www.who.int/tb/publications/2018/WHO_RapidCommunicationMDRRTB.pdf. Accessed 10 January 2019.
5. World Health Organization. Definitions and reporting framework for tuberculosis—2013 revision. Geneva, Switzerland, 2013. Available at: http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf?ua=1. Accessed 10 January 2019.
6. Monedero-Recuero I, Hernando-Marrupe L, Sánchez-Montalvá A, et al. QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment. *Int J Tuberc Lung Dis* 2018; 22:1411–21.
7. Pontali E, Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Migliori GB. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. *Eur Respir J* 2017; 50:1701462.
8. EndTB. Bedaquiline- and delamanid- containing regimens achieve excellent interim treatment response without safety concerns. 2018. Available at: <http://www.endtb.org/resources/endtb-interim-analysis-july2018>. Accessed 5 March 2019.
9. World Health Organization. Position statement on the continued use of the shorter MDR-TB regimen following an expedited review of the STREAM stage 1 preliminary results. 2018. Available at: <http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/WHOPositionStatementShorterRegimensSTREAMStage1.pdf?ua=1>. Accessed 20 January 2019.
10. Bastard M, Guglielmetti L, Huerga H, et al. Bedaquiline and repurposed drugs for fluoroquinolone-resistant multidrug-resistant tuberculosis: how much better are they? *Am J Respir Crit Care Med* 2018; 198:1228–31.
11. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. *Eur Respir J* 2017; 49:1700387.
12. Zhao Y, Fox T, Manning K, et al. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: a retrospective cohort study [manuscript published online ahead of print 24 August 2018]. *Clin Infect Dis* 2018. doi: 10.1093/cid/ciy727.